Literature DB >> 21505069

Ex vivo gene therapy for HIV-1 treatment.

Lisa J Scherer1, John J Rossi.   

Abstract

Until recently, progress in ex vivo gene therapy (GT) for human immunodeficiency virus-1 (HIV-1) treatment has been incremental. Long-term HIV-1 remission in a patient who received a heterologous stem cell transplant for acquired immunodeficiency syndrome-related lymphoma from a CCR5(-/-) donor, even after discontinuation of conventional therapy, has energized the field. We review the status of current approaches as well as future directions in the areas of therapeutic targets, combinatorial strategies, vector design, introduction of therapeutics into stem cells and enrichment/expansion of gene-modified cells. Finally, we discuss recent advances towards clinical application of HIV-1 GT.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21505069      PMCID： PMC3095057          DOI： 10.1093/hmg/ddr160

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN： 0964-6906            Impact factor:   6.150


  88 in total

Review 1.  The use of cell-delivered gene therapy for the treatment of HIV/AIDS.

Authors:  Geoff P Symonds; Helen A Johnstone; Michelle L Millington; Maureen P Boyd; Bryan P Burke; Louis R Breton
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

2.  Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells.

Authors:  Xin Huang; Hongfeng Guo; Syam Tammana; Yong-Chul Jung; Emil Mellgren; Preetinder Bassi; Qing Cao; Zheng Jin Tu; Yeong C Kim; Stephen C Ekker; Xiaolin Wu; San Ming Wang; Xianzheng Zhou
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

3.  Targeting HIV-1 DNA integration by swapping tethers.

Authors:  Robert Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-09       Impact factor: 11.205

4.  Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.

Authors:  Lisa A Lopez; Su Jung Yang; Heiko Hauser; Colin M Exline; Kevin G Haworth; Jill Oldenburg; Paula M Cannon
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

5.  Cytoplasmic body component TRIM5{alpha} requires lipid-enriched microdomains for efficient HIV-1 restriction.

Authors:  Seiga Ohmine; Ryuta Sakuma; Toshie Sakuma; Tayaramma Thatava; Gonzalo P Solis; Yasuhiro Ikeda
Journal:  J Biol Chem       Date:  2010-09-01       Impact factor: 5.157

6.  The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.

Authors:  Chunling Hu; Dyana T Saenz; Hind J Fadel; William Walker; Mary Peretz; Eric M Poeschla
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

7.  Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.

Authors:  Janine Kimpel; Stephen E Braun; Gang Qiu; Fay Eng Wong; Michelle Conolle; Jörn E Schmitz; Christian Brendel; Laurent M Humeau; Boro Dropulic; John J Rossi; Annemarie Berger; Dorothee von Laer; R Paul Johnson
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

8.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

9.  A single amino acid substitution of the human immunodeficiency virus type 1 capsid protein affects viral sensitivity to TRIM5 alpha.

Authors:  Ayumu Kuroishi; Katarzyna Bozek; Tatsuo Shioda; Emi E Nakayama
Journal:  Retrovirology       Date:  2010-07-07       Impact factor: 4.602

10.  Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.

Authors:  Ilias Christodoulopoulos; Magali E Droniou-Bonzom; Jill E Oldenburg; Paula M Cannon
Journal:  Retrovirology       Date:  2010-01-26       Impact factor: 4.602
View more
  13 in total

Review 1.  HIV/AIDS eradication.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Bioorg Med Chem Lett       Date:  2013-05-18       Impact factor: 2.823

2.  Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity.

Authors:  Janet Karpinski; Ilona Hauber; Jan Chemnitz; Carola Schäfer; Maciej Paszkowski-Rogacz; Deboyoti Chakraborty; Niklas Beschorner; Helga Hofmann-Sieber; Ulrike C Lange; Adam Grundhoff; Karl Hackmann; Evelin Schrock; Josephine Abi-Ghanem; M Teresa Pisabarro; Vineeth Surendranath; Axel Schambach; Christoph Lindner; Jan van Lunzen; Joachim Hauber; Frank Buchholz
Journal:  Nat Biotechnol       Date:  2016-02-22       Impact factor: 54.908

3.  Controversies in HIV cure research.

Authors:  Rowena Johnston; Françoise Barré-Sinoussi
Journal:  J Int AIDS Soc       Date:  2012-03-16       Impact factor: 5.396

Review 4.  Creating genetic resistance to HIV.

Authors:  John C Burnett; John A Zaia; John J Rossi
Journal:  Curr Opin Immunol       Date:  2012-09-15       Impact factor: 7.486

Review 5.  Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.

Authors:  C W Peterson; P Younan; K R Jerome; H-P Kiem
Journal:  Gene Ther       Date:  2013-01-31       Impact factor: 5.250

6.  Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice.

Authors:  Ilona Hauber; Helga Hofmann-Sieber; Jan Chemnitz; Danilo Dubrau; Janet Chusainow; Rolf Stucka; Philip Hartjen; Axel Schambach; Patrick Ziegler; Karl Hackmann; Evelin Schröck; Udo Schumacher; Christoph Lindner; Adam Grundhoff; Christopher Baum; Markus G Manz; Frank Buchholz; Joachim Hauber
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

7.  Hematopoietic cell transplantation with cord blood for cure of HIV infections.

Authors:  Lawrence D Petz; Istvan Redei; Yvonne Bryson; Donna Regan; Joanne Kurtzberg; Elizabeth Shpall; Jonathan Gutman; Sergio Querol; Pamela Clark; Richard Tonai; Sarah Santos; Aide Bravo; Stephen Spellman; Loren Gragert; John Rossi; Shirley Li; Haitang Li; David Senitzer; John Zaia; Joseph Rosenthal; Stephen Forman; Robert Chow
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-23       Impact factor: 5.742

8.  A SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication.

Authors:  Hui Feng; Jürgen Beck; Michael Nassal; Kang-Hong Hu
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

9.  Recombinant interferon-γ lentivirus co-infection inhibits adenovirus replication ex vivo.

Authors:  Ling Zhang; Sen Yin; Wanlong Tan; Dong Xiao; Yunceng Weng; Wenjing Wang; Tingting Li; Junwen Shi; Lifang Shuai; Hongwei Li; Jianhua Zhou; Jean-Pierre Allain; Chengyao Li
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

10.  Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.

Authors:  Gene-Errol E Ringpis; Saki Shimizu; Hubert Arokium; Joanna Camba-Colón; Maria V Carroll; Ruth Cortado; Yiming Xie; Patrick Y Kim; Anna Sahakyan; Emily L Lowe; Munetoshi Narukawa; Fadi N Kandarian; Bryan P Burke; Geoff P Symonds; Dong Sung An; Irvin S Y Chen; Masakazu Kamata
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.